Silence Therapeutics Appoints New CEO

August 21, 2007
BioPharm International Editors

Silence Therapeutics (London, England, www.silence-therapeutics.com) has appointed Jeffrey Scott Vick as Group CEO.

Silence Therapeutics (London, England, www.silence-therapeutics.com) has appointed Jeffrey Scott Vick as Group CEO. With this appointment, the company hopes to strengthen its core management team and expand its business partnerships. Vick has held senior positions in the healthcare industry in both Europe and the US, gaining experience as a business analyst and biotech venture capitalist. He has worked in the drug development sector for five years in senior management roles with DepoTech Corporation.

Related Content:

News